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Abstract  
Background: Current phenotyping of chronic rhinosinusitis (CRS) into CRS with nasal 
polyps and without nasal polyps may not adequately reflect the pathophysiologic diversity 
within CRS.  
Objective: We sought to identify inflammatory endotypes of chronic rhinosinusitis. 
Therefore, we aimed to cluster CRS subjects solely based on immune markers in a phenotype-
free approach. Secondarily we aimed to match clusters to phenotypes. 
Methods: In this multicenter case-control study, CRS cases and controls underwent surgery, 
and tissue was analyzed for IL-5, IFN-γ, IL-17A, TNF-α, IL-22, IL-1β, IL-6, IL-8, ECP, 
MPO, TGF-β1, IgE, Staphylococcus aureus enterotoxin specific IgE (SE-IgE), and albumin. 
We used using partition-based clustering.  
Results: Clustering of 173 cases resulted in 4 clusters with low or undetectable IL-5, ECP, 
IgE and albumin concentrations, and 6 clusters having high concentrations of those markers. 
Three of four IL-5-negative clusters had no inflammation, a Th22, or a Th1 profile, and 
clinically resembled a predominant CRSsNP phenotype without increased asthma prevalence. 
One had a Th17 profile and had mixed CRSsNP/CRSwNP. The IL-5-positive clusters were 
divided in a group of three clusters with moderate IL-5 concentrations, mixed 
CRSsNP/CRSwNP and increased asthma phenotype, and a group with high IL-5 levels, 
almost exclusive nasal polyp phenotype and strongly increased asthma prevalence. In the 
latter, two clusters demonstrated highest concentrations of IgE and asthma prevalence with all 
samples expressing SE-IgE. 
Conclusion: Distinct CRS clusters with diverse inflammatory mechanisms largely correlated 
with phenotypes and further differentiated them, and provide a more accurate description of 
the inflammatory mechanisms involved than phenotype information only.  
 
  
Key messages: Chronic rhinosinusitis consists of several inflammatory endotypes defined by 
the composition of inflammatory markers; those endotypes correlate with the clinical 
expression of disease and asthma.  
Key words: Chronic rhinosinusitis with and without nasal polyps (CRSwNP, CRSsNP), 
endotypes, cluster analysis, inflammation, comorbid asthma 
Capsule summary: Phenotypes in chronic rhinosinusitis may further be differentiated in 
inflammatory endotypes, reflecting different pathophysiological mechanisms, and may help to 
determine therapeutic targets 
  
Abbreviations: 
CRS: chronic rhinosinusitis 
CRSsNP: chronic rhinosinusitis without nasal polyps 
CRSwNP: chronic rhinosinusitis with nasal polyps 
ECP: eosinophilic cationic protein 
IFN: interferon 
IgE: immunoglobulin E 
IL: interleukin 
MPO: myeloperoxidase 
SE-IgE: Staphylococcus aureus enterotoxin specific IgE 
TGF: transforming growth factor 
Th: T-helper 
TNF: tumor necrosis factor 
  
Introduction 
Chronic rhinosinusitis (CRS) is a disabling disease affecting 10.9% of the European 
1
 and 
13.4% of the American 
2
 general population. CRS is defined by symptoms and clinical signs, 
and diagnosis may be supported by nasal endoscopy and CT scanning 
3
. In a European 
multicenter epidemiological study involving 56,000 individuals, it recently has been 
demonstrated that cigarette smoking increases the risk of CRS 
1
; of interest, CRS is also 
associated with late-onset asthma 
4
. However, questionnaire-based population studies are 
limited in further defining possible subgroups relevant for these associations 
5
. Indeed, CRS 
shows remarkable heterogeneity, both at the clinical phenotype level and at the molecular 
pathophysiological level. Current consensus in Europe and the US discerns two major 
phenotypes - defined as subgroups of patients with homogeneous clinically observable 
characteristics 
6
 - based on nasal endoscopic findings: chronic rhinosinusitis with nasal polyps 
(CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). Furthermore, there are 
additional subtypes such as allergic fungal rhinosinusitis, CRS associated with aspirin-
exacerbated respiratory disease, and with cystic fibrosis which may present as CRSwNP or 
CRSsNP 
3
.  
The clinical dichotomization of CRSwNP vs. CRSsNP was initially reflected at the molecular 
level, showing a predominance of Th1 cells in CRSsNP and of Th2 cells and eosinophils in 
CRSwNP in Caucasians 
7, 8
. However, subsequent studies reported a wider spectrum of 
immunologic profiles, especially in non-Caucasian phenotypes 
9
, expressing a neutrophilic 
type of inflammation with involvement of other T-cell subsets such as Th1 and Th17 cells. 
Furthermore, the simultaneous expression of different Th cell types within a single tissue was 
demonstrated 
10
. 
Thus, the simple differentiation in Th1 and Th2 disease does not encompass the molecular 
diversity in CRS, and the clinical phenotype does not adequately identify the immunological 
profile. Therefore we sought to identify inflammatory endotypes of CRS – defined as 
“subtypes of disease with a unique pathomechanism, functionally and pathologically different 
from others by the involvement of a specific molecule or cell”. 11 For this, we aimed to cluster 
CRS subjects solely based on immune markers in a clinical phenotype-free approach. 
Secondarily, we aimed to match these endotypes with clinical phenotypes and with selected 
clinical parameters, of which we already have identified association with immune markers 
12, 
13
. This approach would also facilitate the identification of therapeutic targets and predict 
response to those approaches, e.g. biologicals. 
 
Methods 
Study design 
The study was designed as a multicenter case-control study carried out by the Ga²len Sinusitis 
Cohort group (principal investigator C. Bachert) in the framework of the European FP6 
research initiative. The ENT departments in tertiary referral academic hospitals of Ghent, 
Leuven, Amsterdam, Barcelona, London, Berlin, Helsinki, Lodz, Malmö, and Stockholm 
participated in this study. This study was approved by the ethical committees of all individual 
institutions involved in data and tissue collection. Informed consent was obtained from all 
subjects before sample collection.  
Patient population 
Patients with CRS (defined by EPOS-criteria based on symptoms, nasal endoscopy and 
computed tomography of the sinuses 
3
) were included as cases, and subjects undergoing 
inferior turbinate surgery with no signs of CRS were included as controls. Excluded were 
subjects with an acute exacerbation of rhinosinusitis 2 weeks preceding inclusion, subjects 
with immunodeficiencies, cystic fibrosis patients, and subjects who used oral or nasal steroids 
in the 4 weeks preceding surgery, or anti-leukotrienes in 2 weeks preceding inclusion. In total, 
917 subjects were recruited, of whom 682 cases (of which 65% CRSwNP) and 187 controls. 
Subjects underwent a standardized skin prick test 
14
 and subjects were registered as asthmatic 
based on a clinical diagnosis. Patients were considered allergic on clinical grounds (positive 
skin prick test or provocation tests or specific IgE to inhalant allergens plus allergy symptoms 
present). 
At a maximum of 12 months after inclusion, a portion of the subjects underwent functional 
endoscopic sinus surgery, and controls underwent partial inferior turbinotomy during septal 
surgery (226 CRS patients and 106 controls). Controls having allergic rhinitis were not 
excluded. The indications for surgery and its procedures were based on clinical decisions 
independent from the participation in the study. Tissue was collected from nasal polyps or 
sinus mucosa in patients with CRS, and from the inferior turbinates in control subjects. Tissue 
was separated from bone fragments, snap-frozen in liquid nitrogen and stored at -80°C. 
Control tissues were not used in the cluster analyses of the CRS patients, but solely served to 
determine increased concentrations of markers above normal.  
Measurement of inflammatory markers 
For tissue analysis, we selected 14 markers (Table 1) based on earlier publications; those 
markers reflect the inflammatory patterns observed in CRSsNP and CRSwNP. Only subjects 
of which there was an adequate amount of tissue that was needed for these analyses (typically 
0.15g), were included. Briefly, as described before 
15
, each 0.1g of tissue was diluted in 1mL 
of 0.9% NaCl solution containing a protease inhibitor cocktail (Complete®, Roche 
Diagnostics, Mannheim, Germany), homogenized at 1000 rpm for 5 min and centrifuged at 
1500 g for 10 min at 4°C. Concentrations of eosinophilic cationic protein (ECP), total 
immunoglobulin E (IgE) and IgE specific to a mixture of S. aureus enterotoxins (SEA, SEC, 
and TSST-1) were assayed using the UNICAP system (Phadia, Uppsala, Sweden). 
Concentrations of IL-22, IFN-γ, and TGF-β1 were assayed using commercially available 
enzyme-linked immunosorbent assay (ELISA) kits from R&D systems (Minneapolis, MN, 
USA). Myeloperoxidase (MPO) concentration was measured using a commercially available 
ELISA from BioCheck, Inc (Foster City, CA, USA). For albumin we used kits from AssayPro 
(St. Charles, MO, USA). Concentrations of IL-1β, IL-5, IL-6, IL-8, IL17A and TNF-α were 
assayed using the Luminex 100 system (Luminex, Austin, TX, USA).  
Concentrations in tissue homogenates were expressed as mass versus volume after 
multiplication with the homogenization dilution factor of 11. Values below the limit of 
detection were considered negative for categorical analysis and were given a value equal to 
half of the detection limit for continuous analysis. 
Statistical methods 
Statistical software R version 2.15.2 was used 
16
. The following variables which had a high 
proportion (>33%) of values below detection limit were used as binomial variables, with their 
detection limits used as cut-off: SE-IgE (cut-off 3.85 kUA/L), IFN-γ (85.8 pg/mL), TNF-α 
(38.94 pg/mL), IL-17A (25.06 pg/mL), IL-5 (12.98 pg/mL). Baseline parameters were tested 
for difference between cases and controls using t-test on continuous and chi-squared test on 
discrete variables.  
To analyze relationships between variables, we performed principal component analysis, after 
which orthogonal rotation with Kaiser normalization was performed, and only variables with 
loadings higher than 0.4 were retained. Next, we performed cluster analysis on the variables 
using ascendant hierarchical clustering based on the correlation ratio and the mixed principal 
component analysis (
17
, and the optimal number of cluster was determined using the Rand 
statistic. 
For cluster analysis of individual cases, a dissimilarity matrix according to Gower was 
calculated, which allows both ordinal and binomial data. Next, clusters were calculated using 
the partitioning around medoids method, of which outcomes with the number of clusters 
ranging from 2 to 15 clusters were generated. The optimal number of clusters was based on 
the elbow (maximum change) of the scree plot of the mean silhouette width, Baker-Hubert 
Gamma statistic 
18
, and Hubert-Levin C index 
19
. Additionally, the optimal number of clusters 
was assessed using Jaccard stability after bootstrap resampling 
20
 and visual inspection of the 
clusplot after multidimensional scaling
20
. 
For descriptive characterization of individual clusters, cytokine and phenotype data from each 
cluster were tested for difference from the control group (Mann Whitney U and logistic 
regression). Next, between-cluster differences of all parameters, as well as phenotype 
parameters, were tested using Kruskal-Wallis with multiple group comparison with 
Benjamini-Hochberg adjustment for multiple testing, or Tukey contrasts in logistic models for 
binomial parameters. For visualization of clusters, a “clusplot” was drawn, plotting 
individuals in two dimensions after multidimensional scaling. 
As an aid in interpretation of inflammatory patterns, each cytokine in each cluster was 
categorized as increased compared to controls only, and increased compared to controls and 
to 2, 3 or 6 other clusters, or no difference from control or other clusters. Furthermore, for 
each cluster we interpreted the inflammatory patterns based on a high proportion of positive 
categorical variables or on increased concentrations of continuous variables, compared to 
controls and other clusters. The pattern for interpretation is listed in Table 1. A modified 
heatmap was created (Figure 3), after ordering and grouping clusters with similar 
characteristics, and ordering variables according to the previous principal component analysis. 
The variables that were used categorically in the cluster analysis, were additionally tabulated 
with their continuous values. 
Results 
Of the 226 cases and 106 controls who underwent surgery, 173 cases and 89 controls had 
adequate amount of tissue prelevated to carry out all intended analyses. Demographic, 
phenotypic and cytokine data of cases and controls are tabulated in Table 2; demographic data 
of the sample included were not different from the total cohort. Cases had a significantly 
higher age, and had a higher prevalence of smoking history and asthma. Cases had 
significantly higher concentrations than controls of IL-6, IL-8, albumin, MPO, ECP, IgE, and 
had significantly higher proportion of concentration above detection limit for IL-5, IFN-γ and 
SE-IgE (see Table 2). 
Principal component analysis (illustrated in Table E1 and Figure 1A-B) retained 5 
components, explaining 74% of all variance in the data. The first component was composed 
of MPO, IL-1β, IL-6 and IL-8. The second component consisted of IgE, ECP, IL-5 and 
albumin. The third component had TNF-α, IL-17 and IL-22. The fourth component was 
composed of TGF-β and SE-IgE, and the last component of IFN-γ and SE-IgE. In a 
hierarchical cluster analysis of variables (illustrated in figure 1C), these were optimally 
clustered in the 6 following clusters: (1) IgE, ECP, IL-5, albumin, SE-IgE (2) IL1, IL6, IL8, 
MPO, (3) IL17, TNF-α, (4) TGF-β1 (5) IL-22 and (6) IFN-γ.  
Clustering of all CRS individuals using cytokine measurements, irrespective of phenotype 
information, resulted in an optimal outcome of 10 clusters (details are given in Figure E1 and 
Table E2). The clusters were well separated from each other, as illustrated in the cluster plot 
(Figure 2). Tests for between-cluster differences and differences from controls showed that 
for all cytokines, except TGF-β1 and IL-1β, there was at least one cluster having significantly 
higher concentrations than any other cluster. Compared to the control group, all cytokines 
except TGF-β1 were significantly increased (p<0,05) in at least one cluster. Not all clusters 
that had a significant difference from the control group, had differences with other clusters. 
IL-22 concentrations did not differ significantly from controls, however there were multiple 
significant between-group differences.  
Analogously, clinical parameters (which were not used in the cluster analysis) were analyzed 
within clusters and compared with controls (Figure 3). The proportion of CRSwNP was 
significantly different between clusters, with clusters 1-3 significantly lower than most 
clusters and clusters 8-10 significantly higher than most clusters. Asthma prevalence was 
significantly different from controls , and differed significantly between clusters. Age, gender, 
prevalence of allergy and of reported aspirin sensitivity were not significantly different 
between clusters (Table E3).  
To characterize the clusters, means and ratios of cytokine and phenotype data were calculated 
and tabulated as a heatmap (Figure 3). The most striking differentiation was formed by the IL-
5/ECP/IgE/albumin axis, resulting in four clusters having undetectable or low concentrations 
of these biomarkers, and six clusters having high concentrations. The endotype differentiation 
was also reflected in the clinical phenotypes, with three clusters (1-3) showing a predominant 
CRSsNP appearance, four clusters (4-7) a mixed phenotype, and the three clusters (8-10) 
showing a predominant CRSwNP appearance. Clusters 1-3 showed no increase in asthma 
prevalence, whereas clusters 4-10 the asthma prevalence was increased compared to controls 
and to clusters 1-3, with further increases in clusters 9 and 10.  
The 4 clusters with predominant non-eosinophilic appearance could further be differentiated 
as follows: cluster 1 did not show any signs of inflammation (no single cytokine was 
significantly increased compared to controls in this cluster); cluster 2, a pure CRSsNP cluster, 
overexpressed TNF-α and IL-22, and cluster 3 overexpressed IFN-γ and MPO/IL-8. Cluster 4, 
in contrast, showed a neutrophilic inflammation with upregulation of pro-inflammatory 
cytokines IL-1β/6, IL-8/MPO, as well as IL-17A, -/22, TNF-α and partially IFN-γ.  
The latter 6 clusters were characterized by the expression of IL-5 in every single subject. 
These clusters also expressed increased ECP and total IgE concentrations. This IL-5 positive 
group could be further differentiated in a group of three clusters with mean concentrations of 
IL-5 between 100 to 151 pg/ml (moderate expression group), and a high expression group 
(257 to 483 pg/ml) including clusters 8 to 10. In parallel, with the eosinophilic inflammation, 
there was a neutrophilic inflammation with increased concentrations of IL-8, MPO in clusters 
6 -10. 
The IL-5 moderate expression group (clusters 5-7) was predominantly, but not exclusively 
consisting of the CRSwNP phenotype. Further differentiation within these groups was made 
by co-expression of IFN-γ (cluster 6), or TNF-α and increased IL-22 (cluster 7). The high 
expression group (clusters 8-10) was almost exclusively composed of nasal polyps, and had 
highest levels of albumin, IL-6 and IL-8. Additionally cluster 8 and 10 showed a Th17-family 
based inflammation. Clusters 9 and 10 demonstrated the highest concentrations of tIgE 
(around 1000 kU/l) and the highest rate of co-morbid asthma with 64-71%. All samples in 
these two clusters expressed SE-IgE antibodies in the tissue.  
  
Discussion 
We here present inflammatory endotypes of chronic rhinosinusitis, based on a cluster analysis 
solely based on biomarkers, and secondarily we correlate these to clinical characteristics 
(phenotypes). In this cohort of European subjects who underwent surgery for CRS, we 
observed considerable variability in the data, so that multiple homogeneous subgroups 
(clusters) could be differentiated. This observation indicates that CRS is not a homogeneous 
inflammatory disease, and endotypes are present with a wide diversity of inflammatory 
profiles. To our knowledge, this is the first study to report the existence of inflammatory 
endotypes within CRS, unbiased by phenotype data. Furthermore, we demonstrated that the 
newly defined endotypes mirror clinical phenotypes, supporting their clinical relevance.  
To determine which parameters were relevant in the generation of this diversity, principal 
component analysis and clustering of variables showed that diversity in our samples was 
driven by five groups of related cytokines: (1) markers of eosinophilic, Th2-driven 
inflammation and antibody production (ECP, IL-5, IgE and SE-IgE) together with albumin (2) 
neutrophilic and pro-inflammatory cytokines (IL1β, IL6, IL8, MPO) (3) Th17 or Th22 related 
markers (IL-17A, IL-22, TNF-α, and (4) the Th1 marker IFN-γ. Moreover, TGF-β1 had a 
separate but small contribution to variability in our subjects.  
These observations have previously been observed, albeit in specific CRS subgroups. The 
correlations of ECP, IL5 and IgE confirm previous data in Caucasian nasal polyps, where 
inflammation is dominated by activated eosinophils 
15
 and IgE concentrations were related to 
eosinophilic inflammation
21
. The association of albumin with eosinophil products can be 
related to observations in nasal polyps where increased albumin deposition has been thought 
to be caused by eosinophil-driven inflammation 
15
. The expression of neutrophilic and pro-
inflammatory cytokines has been observed previously in Chinese nasal polyp patients 
9
 and 
more specifically in Chinese nasal polyp patients that were IL-5/IL-17/IFN-γ negative 22.  
Importantly, our observations were present in the whole CRS group, whereas previous results 
were limited to specific subgroups, implicating that that these previously described 
mechanisms can be extrapolated to the overall CRS group, and might not be restricted to the 
CRSwNP phenotype. Indeed, separate post hoc analyses in the CRSsNP and CRSwNP 
subgroup yielded similar principal components (data not shown), indicating that even in the 
lower concentration ranges, concentration gradients of cytokines are present and meaningful. 
These findings indicate that CRS is not a dichotomal or a one-dimensional linear spectrum of 
diseases but rather multidimensional with different polarizations on the main inflammatory 
axes.  
When individuals were clustered into inflammatory endotypes, our analysis resulted in 10 
clusters of which each cytokine pattern was interpreted, and accordingly, clusters could be 
grouped together (summarized in Figure 4). To characterize each cluster’s phenotype, we 
correlated clusters with selected phenotype parameters such as nasal polyp prevalence and 
asthma comorbidity. Importantly, this was a post-hoc analysis, and the phenotype information 
was not used during cluster analysis. 
We show a strong correlation with the phenotype, with three clusters almost exclusively 
composed of CRSsNP without asthma comorbidity, and three clusters almost exclusively of 
CRSwNP with strongly increased asthma prevalence. Presence of IL-5 remains the paramount 
factor dictating the phenotype with nasal polyps and asthma, in line with previous evidence 
13
. 
SE-IgE presence remains associated with nasal polyps with intense eosinophilic inflammation 
with very high IgE concentrations, and asthma comorbidity, as demonstrated before 
13
. As 
summarized in Figure 4, clusters can accordingly be grouped in four IL-5 negative clusters, 
three moderately increased IL-5 positive clusters, and three IL-5 high clusters of which two 
SE-IgE positive clusters. 
However, in clusters 4 to 7 there is a mixture of phenotypes, with polyp prevalence around 50 
to 60% and albumin moderately increased, although each of these clusters had a distinct 
inflammatory profile. Three of these clusters had moderate increase in IL-5 concentrations 
and further had an eosinophilic pattern, but differed in terms of IFN-γ and TNF-α expression. 
This might indicate that for some groups, IL-5 is not the only key to edema and polyp 
formation, and other, possibly unmeasured factors might play a role in differentiation towards 
a polyp. Our study was limited to the major cytokines, and the amount of tissue available 
limited further analyses. Also, subjects were allocated to a phenotype during office endoscopy 
before surgery, and the clinical differentiation might be unclear in some cases were polyps 
were only observed during surgery. In cases of middle turbinate-confined polypoid oedema, 
the phenotype might not be clear-cut during office endoscopy, and it has been shown that 
early stage nasal polyps already show eosinophilic inflammation 15, 23. Furthermore this 
overlap may be inherent to the concept of phenotype, which, as has been shown in asthma 
phenotyping, fail to provide adequate insight in the underlying pathogenic mechanisms 
24
. 
Within the non Th2 group, inflammation is variable, from being completely absent to broad, 
involving Th1, Th17 or Th22. The role for Th1 in only a part of the IL-5 negative subjects 
contrasts with earlier findings, showing increased levels of IFN-γ protein and mRNA in 
CRSsNP subjects
8
. This could be explained, however, by the averaging effect of former 
analysis approaches. One of the overlapping clusters (4) had no eosinophils or IL-5, and in 
contrast a Th17 – neutrophilic type inflammation. Possibly this endotype is the same as what 
has been observed before in Chinese nasal polyps
9
. Interestingly, it was recently shown that 
second-generation Asian CRSwNP patients in USA showed a higher rate of non-eosinophilic 
polyps than Caucasians 
25
. Unfortunately, we had no ancestry information in our study to 
further analyze this relationship. 
The production of Th17-family derived cytokines IL-17A and IL-22 correlated modestly as 
was shown by the principal components analysis. Reasons for this modest correlation are 
apparent when analyzing the cluster profiles; in cluster 4 and 8 the IL-17A production was 
paired with increased IL-22 production whereas in clusters 2 and 7, only increased IL-22 
production was present, possibly indicating Th22 involvement in these clusters. Interestingly, 
in cluster 10, which was a SE-IgE positive cluster, the increased IL-22 production was paired 
with only marginal IL-17A production, indicating a Th22 involvement which also was 
observed to be induced by staphylococcal enterotoxins in atopic dermatitis 
26
. Additionally, 
we observed increased TNF-α levels in all of these clusters, consistent with the observation 
that both Th17 and Th22 cells may induce TNF-α production27. However, IL-22 
concentrations did not differ from controls, and this effect remained after excluding allergic 
controls (data not shown). The reasons for this discrepancy with coherent between-cluster 
differences are not clear and the relevance of Th22 in the pathology of CRS should be further 
elucidated. 
Surprisingly, we found little contribution of TGF-β1 to the variability of our data; the TGF-β1 
concentration had no significant between-cluster differences and did not differ between 
clusters and the control group. Previously, expression of TGF-β signaling was in Caucasians 
found to be increased in CRSsNP, sharply contrasting to a decreased signaling in CRSwNP 
28
. 
These findings were later confirmed in Chinese CRS subjects
29
, although these are 
characterized by different T effector cell profiles than their Caucasian counterparts 
9
. In our 
study, CRSsNP subjects were confirmed to have increased TGF-β1 concentrations compared 
to CRSwNP subjects and controls (p<0.001, data not shown). However, we did not have 
adequate amounts of tissue to further analyze remodeling patterns and T regulatory cell 
involvement. Taken together, these findings might indicate that remodeling is strongly 
correlated with the phenotype (fibrosis vs. edema formation), irrespective of the inflammatory 
endotype.  
Some of the broad characteristics of this clustering are found in a previous cluster analysis by 
Nakayama
30
 who proposed a clustering where nasal polyp score and tissue eosinophilia 
mainly determined the phenotype. Interestingly, in a recent cluster analysis of CRS subjects 
focusing on symptoms and clinical information, nasal polyposis did not differ between 
phenotypes
31
. However, these approaches are inherently different from our study, as we based 
our cluster analysis solely on inflammatory mediators to obtain endotypes, and only in a post-
hoc analysis we compared these with selected phenotype parameters such as nasal polyp 
prevalence and asthma comorbidity. 
Our study has some limitations. Our definition of endotypes was entirely based on 
inflammatory biomarkers. However, for asthma, it is proposed that more parameters, such as 
clinical characteristics, genetics and treatment responses should be included for the definition 
of an endotype
33. We aimed to propose ‘inflammatory endotypes’, and further studies are 
needed incorporating clinical characteristics, genetics, remodeling parameters, and treatment 
responses to further define these endotypes. Some of these endotypes might eventually be 
merged or split with other endotypes given these additional studies. 
The use of cluster analysis is potentially a limiting factor in this study. As cluster analysis is 
no inferential statistical technique, there is no probability outcome. The technique generates 
multiple possible solutions in terms of number of clusters, of which the most relevant solution 
is selected by the examiner. To scrutinize this process, the selection of the best number of 
clusters was based on objective criteria such as the Hubert-Levine index as a measure of 
internal cluster validity, as well as bootstrap resampling of the cluster analysis. Even though 
all these measure resulted in a certain optimal number of clusters, it is not our aim to claim a 
final definite classification in which all CRS subjects should be categorized, but instead, 
illustrate the diversity in inflammatory profiles.  
The inflammatory profile of asthmatics has been found to evolve over time within subjects. 
As we only analyzed our subjects on one time point, possible variability of the inflammatory 
endotype over time limits our findings. Indeed, when comparing the profile of nasal polyp 
patients undergoing two surgeries due to disease recurrence, it has been found that all nasal 
polyps remained IL-5 positive over a period of in average 5 years, however in some patients 
IL-17 became co-expressed
12
. To determine the clinical and therapeutic utility of the 
inflammatory endotypes, further longitudinal studies are needed, evaluating their stability 
over time, in relation to possible treatment and environmental changes. 
The applicability of our study, which was done in a European population, to other regions in 
the world, remains at question as well. For example, the high smoking prevalence in our study 
was comparable to the European average, but lower smoking prevalences in North America 
might affect the inflammatory endotype.  Other lifestyle and environmental factors might 
affect the endotype, and global studies are needed to address these. 
Furthermore, Our choice of biomarkers did not cover remodeling parameters, and we have not 
included cellular contents. However, the current analysis enables the appreciation of the 
possible target groups for various therapeutic monoclonal antibodies currently in study.  
In summary, we have identified distinct inflammatory endotypes within chronic 
rhinosinusitis, which largely correlated with phenotypes and further differentiated them. 
Endotypes clearly provide a more accurate description of the inflammatory mechanisms 
involved than phenotype information only, and inflammation in CRS may be more diverse 
than previously assumed. CRS inflammation should be considered as multidimensionally 
heterogeneous on the Th1, Th2, Th17, eosinophilic/neutrophilic, pro-inflammatory, 
superantigen and possibly Th22 axes. Inflammatory endotypes might be of importance for the 
prognosis of comorbid asthma development or disease recurrence after surgery
12
.  As recent 
monoclonal antibody approaches such as omalizumab 
34
, mepolizumab 
35
 or dupilumab target 
specific cytokines or pathways, it is expected that an approach based on biomarker-defined 
clusters would identify responders to these drugs. Nasal levels of IL-5 for example were 
found to predict responders to reslizumab, an anti-IL5 monoclonal antibody
36
. The clinical 
applicability of inflammatory endotypes, however, would be aided by the availability of 
noninvasive serum or nasal secretion markers; a range of markers is currently under 
investigation in the same cohort of CRS patients.  
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Figure legends 
Figure 1. Principal component analysis and clustering of variables. A: Vectors of each 
parameter are plotted against the first four rotated principal components. A1: First two 
principal components, B: Third and fourth principal component. The fifth rotated component 
is not depicted, it consisted of IFN-γ and SE-IgE. C. Dendrogram of clustered variables. 
Horizontal dashed line indicates the tree cut used in this analysis, based on the Rand index 
and resulting in 6 variable clusters. 
Figure 2 Cluster plot of cases. Clustering of cases illustrated in a clusplot where individuals 
are plotted in a two-dimensional space after multidimensional scaling. Here, dissimilarities 
between individuals, taking in account all variables, are represented by distances between the 
individuals in two dimensions.  
Figure 3. Modified heat map of clustering of individual cases.  
Rows define clusters of CRS cases; these were arbitrarily (non-hierarchically) ordered 
according to the cytokine pattern. Columns indicate the variables used for cluster analysis, 
which were ordered according to their interrelationship in component analysis. Geometric 
mean concentrations are given for each cluster. Some variables were used in the cluster 
analysis in a categorical manner because of a high rate of below detection limit measurements 
(IFN-γ, IL-5, SE-IgE, TNF-α and IL-17). For these, proportion of positive values are given, 
and additionally geometric means are given for illustrative purposes. Selected phenotypic 
information (proportion with nasal polyps, with asthma, allergy) is tabulated, although not 
used in cluster analysis. For characterization of the clusters, multiple group comparison for 
between-cluster differences, and for differences with the control group, is visualized with a 
color code as in legend. For CRSwNP proportion, only between-cluster differences were 
calculated. *In clusters 2,4,7,8, IL-22 concentrations were significantly higher than in clusters 
1,5,6 and 9, but were not different from controls. 
Figure 4. Summary graph. Simplified graphical depiction of the clusters and their 
characteristic cytokines as well as the distribution of CRSsNP vs CRSwNP and asthma. For 
cytokines, white color indicates no increased concentration, light colors indicate moderately 
increased concentration and  dark colors indicate strongly increased concentration. Horizontal 
lines indicate groups of clusters as determined by IL-5, SE-IgE and CRSwNP and asthma 
characteristics. 
Figure E1. Validation of clustering. 
We generated different clusterings with a number of clusters (k) ranging from 2 to 15. To 
validate clustering outcomes, we used internal cluster quality measures, as indicated in graphs 
A to F. For each of the possible number of clusters, an index is calculated reflecting the 
between-subject similarity within clusters, and the dissimilarity between clusters. This index 
usually increases monotonically with increasing number of clusters, and the optimal is 
determined to be at the elbow of its plot, where the change in index (difference with k-1 and 
k+1) is at a maximum. There are several possible indices available. We used mean silhouette 
width, Baker-Hubert Gamma statistic, and Hubert-Levin C index as they are relying on 
dissimilarity data (allowing mixed continuous and categorical data, as is the case in our 
sample). We mostly relied on the C index as this is especially fit for mixed type data. The 
following plots show the index for k = 2-15 possible clusters, and the change (delta) in index 
compared to k-1. Note that for the C index lower values are better. The results from the 
internal cluster quality indexes produce a good signal at either 4-5 clusters and 8-10 clusters.  
Secondly we assessed clustering stability after resampling of the cluster analysis. Here, data is 
resampled (for 1,000 iterations) using several schemes (bootstrap, subsetting of the data) and 
clusters are recalculated. The Jaccard similarities of the original clusters to the most similar 
clusters in the resampled data are computed, giving an estimate of the stability of a cluster.  In 
the range of k = 2-15, average stability peaked at 5 and 10 clusters. 
Lastly we assessed cluster validity using visual inspection of the clusterplot. The subjects are 
plotted in a two-dimensional space after multidimensional scaling, which is a technique 
maximizing the dissimilarities between subjects projected in two dimensions. Plots were 
created for the 5 and 10-cluster solution, and are illustrated in pane G and H. The five cluster 
solution clearly showed unresolved clusters, which were correctly discovered in the 10-cluster 
solution. 
 
Table 1: Markers used for the component and cluster analysis*  
 
Marker Cut-off value Interpretation of increased concentrations 
IFN-γ 85.8 pg/mL T-helper 1 (Th1) activity 
IL-5 12.98 pg/mL T-helper 2 (Th2) activity 
IL-17A 25.06 pg/mL T-helper 17 (Th17) activity 
IL-22 n.a. T-helper 22 (Th22)  activity 
TNF-α 38.94 pg/mL Pro-inflammatory action 
IL-1β n.a. Pro-inflammatory action 
IL-6 n.a. Pro-inflammatory action 
IL-8 n.a. Neutrophilic chemotaxis 
MPO n.a. Neutrophilic activity marker 
ECP n.a. Eosinophilic activity marker 
IgE n.a. Adaptive immunity marker 
SE-IgE 3.85 kUA/L Marker for superantigen impact on local 
mucosa 
Albumin n.a. Edema 
TGF-β1 n.a. Fibrosis/regulatory T cell activation 
 
* Cut-off values are given for markers that were analyzed as categorical, and a short 
description of the interpretation given regarding the underlying inflammatory pattern when an 
increased concentration or an increased proportion above cut-off was observed. Cut-off values 
are expressed as mass per volume undiluted homogenized tissue, i.e. calculated as the 
detection limit x dilution factor. 
  
Tables - Unmarked
Table 2. Characteristics of cases and controls.  
    cases controls 
cases vs. 
controls (p)   
Mean age (years) 
 
42.8 32.8 <0.001 * 
Gender (% male) 
 
58.2 58.1 0.995 * 
Proportion ever smoker (%) 
 
64.7 47.1 0.005 ° 
Proportion current smoker (%) 
 
29.0 25.9 0.592 ° 
Proportion with allergy (%) 
 
45.0 34.1 0.084 ° 
Proportion with asthma (%) 
 
28.2 15.3 0.019 ° 
Proportion with aspirin sensitivity (%) 
 
4.5 1.1 0.148 ° 
Proportion with CRSwNP (%) 
 
56.6 - - 
 
      Total IgE (kU/L, geometric mean) 
 
87.6 8.9 <0.001 * 
ECP (µg/L, geometric mean) 
 
2348.5 116.6 <0.001 * 
IL-8 (pg/mL, geometric mean) 
 
1798 644 <0.001 * 
IL-6 (pg/mL, geometric mean) 
 
72.8 41.0 0.021 * 
IL-1β (pg/mL, geometric mean) 
 
28.6 23.7 0.3923 * 
TGF-β1 (pg/mL, geometric mean) 
 
9358 8248 0.2282 * 
MPO (ng/mL, geometric mean) 
 
2122 966 <0.001 * 
IL-22 (pg/mL, geometric mean) 
 
363.2 347.5 0.4876 * 
Albumin (µg/dL, geometric mean) 
 
965.2 552.4 <0.001 * 
      IL-17A (% pos.) 
 
32.1 25.3 0.239 ° 
TNF-α (% pos.) 
 
58.4 48.3 0.108 ° 
SE-IgE (% pos.) 
 
12.9 0.0 <0.001 ° 
IFN-γ (% pos.) 
 
26.5 12.5 0.015 ° 
IL-5 (% pos.) 
 
63.4 3.5 <0.001 ° 
 
Concentrations are expressed as mass per volume undiluted homogenate. *Student's T-test 
°Pearson's Chi-square. %pos: proportion samples above cut-off value. 
 
Table E1. Coordinates of principal component analysis for the first five orthogonally rotated 
principal components*.  
 
  Comp.1 Comp.2 Comp.3 Comp.4 Comp.5 
IgE 
 
0.846 
   ECP 
 
0.84 
   TNF-α 
  
0.678 
  IL-8 0.876 
    IL-17A 0.611 
 
0.442 
  IL-6 0.76 0.432 
   IL-5 
 
0.904 
   IL-1β 0.867 
    IFN-γ 
    
0.857 
MPO 0.811 
    IL-22 
  
0.741 
  TGF-β1 
   
0.873 
 Albumin 
 
0.69 
   SE-IgE 
   
0.423 0.47 
      Variance explained (%) 25% 22% 10% 9% 8% 
Cumulative variance 
explained (%) 25% 47% 57% 66% 74% 
*Variables with coordinates lower than 0.4 were omitted from the component. The proportion 
of total variance in the dataset, explained by each component, is given. Also the cumulative 
proportion of total variance explained by the sum of each of the components and its preceding 
components is given. Comp.: primary component. 
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Table E2. Bootstrap stability of individual clusters in the 10-cluster solution. 
Data is was resampled (for 1,000 iterations) using several schemes (bootstrap, subsetting of 
the data) and clusters are recalculated. The Jaccard similarities of the original clusters to the 
most similar clusters in the resampled data are computed, giving an estimate of the stability of 
a cluster.  In general, values lower than 0,5 indicate unstable clusters, values higher than 0,6 
(*) plausible structure, values higher than 0,75 (**) indicate stable and valid clusters and 
values higher than 0,85 (***) indicate highly stable clusters. 
Cluster Bootstrap 
stability 
 
1 0.98 *** 
2 0.95 *** 
3 0.82  ** 
4 0.87 ** 
5 0.96 *** 
6 0.70 * 
7 0.94 *** 
8 0.77 ** 
9 0.61 * 
10 0.68 * 
 
 
  
Table E3. Clinical characteristics of clusters. 
Cluster Ever 
smoker  
(%) 
Current   
smoker 
(%) 
Aspirin  
sensitivity  
(%) 
Gender 
(% 
female) 
Previous   
surgery  
rate (%) 
1 72 40 0 28 0 
2 81 56 0 31 21 
3 73 53 0 27 8 
4 87 33 7 53 27 
5 46 8 11 35 39 
6 73 18 9 73 30 
7 69 31 7 54 33 
8 64 14 7 29 39 
9 73 36 18 36 50 
10 14 0 0 14 64 
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